Comparison of proteomic technologies for blood-based detection of colorectal cancer

• Verfasst von: Bhardwaj, Megha [VerfasserIn]
• Verfasst von: Terzer, Tobias [VerfasserIn]
• Verfasst von: Schrotz-King, Petra [VerfasserIn]
• Verfasst von: Brenner, Hermann [VerfasserIn]
• Titel: Comparison of proteomic technologies for blood-based detection of colorectal cancer
• Verf.angabe: Megha Bhardwaj, Tobias Terzer, Petra Schrotz-King and Hermann Brenner
• E-Jahr: 2021
• Jahr: 26 January 2021
• Umfang: 17 S.
• Fussnoten: Gesehen am 01.12.2021
• Titel Quelle: Enthalten in: International journal of molecular sciences
• Ort Quelle: Basel : Molecular Diversity Preservation International, 2000
• Jahr Quelle: 2021
• Band/Heft Quelle: 22(2021), 3, Artikel-ID 1189, Seite 1-17
• ISSN Quelle: 1422-0067
• ISSN Quelle: 1661-6596
• DOI: doi:10.3390/ijms22031189
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: biomarkers
• Sach-SW: colorectal cancer
• Sach-SW: diagnosis
• Sach-SW: LC/MRM-MS
• Sach-SW: microarray
• Sach-SW: plasma proteins
• Sach-SW: proximity extension assays
• K10plus-PPN: 1751079570

Abstract

Blood-based protein biomarkers are increasingly being explored as supplementary or efficient alternatives for population-based screening of colorectal cancer (CRC). The objective of the current study was to compare the diagnostic potential of proteins measured with different proteomic technologies. The concentrations of protein biomarkers were measured using proximity extension assays (PEAs), liquid chromatography/multiple reaction monitoring–mass spectrometry (LC/MRM-MS) and quantibody microarrays (QMAs) in plasma samples of 56 CRC patients and 99 participants free of neoplasms. In another approach, proteins were measured in serum samples of 30 CRC cases and 30 participants free of neoplasm using immunome full-length functional protein arrays (IpAs). From all the measurements, 9, 6, 35 and 14 protein biomarkers overlapped for comparative evaluation of (a) PEA and LC/MRM-MS, (b) PEA and QMA, (c) PEA and IpA, and (d) LC/MRM-MS and IpA measurements, respectively. Correlation analysis was performed, along with calculation of the area under the curve (AUC) for assessing the diagnostic potential of each biomarker. DeLong’s test was performed to assess the differences in AUC. Evaluation of the nine biomarkers measured with PEA and LC/MRM-MS displayed correlation coefficients >+0.6, similar AUCs and DeLong’s p-values indicating no differences in AUCs for biomarkers like insulin-like growth factor binding protein 2 (IGFBP2), matrix metalloproteinase 9 (MMP9) and serum paraoxonase lactonase 3 (PON3). Comparing six proteins measured with PEA and QMA showed good correlation and similar diagnostic performance for only one protein, growth differentiation factor 15 (GDF15). The comparison of 35 proteins measured with IpA and PEA and 14 proteins analyzed with IpA and LC/MRM-MS revealed poor concordance and comparatively better AUCs when measured with PEA and LC/MRM-MS. The comparison of different proteomic technologies suggests the superior performance of novel technologies like PEA and LC/MRM-MS over the assessed array-based technologies in blood-protein-based early detection of CRC.